^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Clinical benefit from immunotherapy in patients with small cell lung cancer is associated with tumor capacity for antigen presentation

Published date:
05/17/2023
Excerpt:
CheckMate 032, a multicenter, open-label, phase 1/2 trial evaluating nivolumab alone or with ipilimumab was the largest study of ICB alone in patients with SCLC....Analysis of epigenetic determinants of antigen presentation identified Lysine-Specific Demethylase I (LSD1) gene expression as a correlate of worse survival outcomes for patients treated with either nivolumab or the combination of nivolumab and ipilimumab.
DOI:
https://doi.org/10.1016/j.jtho.2023.05.008
Trial ID: